Skip to Main Content

Paper Details

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
BMC Cancer
23
2018
-, NSCLC, PD-1, PD-L1, Programmed Death 1, Programmed Death Ligand 1, cancer, exomes, immunosuppressive molecule, non-small cell lung cancers, patient, patients, tumor, tumor cell
Author NameAffiliation
Terry A BraunThe University of Iowa
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Taher AbbasiInc.
Shireen ValiInc.
  • 1 - 5

Datasets

Release 1.2